Dipharma Francis

The Dipharma Group is a global CDMO and a leading manufacturer of APIs, New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering about 40 APIs with DMFs registered worldwide.  

Thanks to a workforce of about 600 skilled and highly committed employees, supported by four state-of-the-art CGMP facilities, located in the U.S.A. and Italy, plus commercial sales offices in Italy, the U.S.A. and China, Dipharma is strategically positioned to meet the dynamic needs of the pharmaceutical industry.  

Our fully-equipped Research and Development Centers, supported by the internal Intellectual Property department, drive innovation by developing cutting-edge chemical processes and crystalline forms tailored to meet the unique requirements of our customers. 
Since 1970, Dipharma has managed to achieve a positive unbroken record of inspections by the major Regulatory Agencies and the CGMP manufacturing sites are equipped to supply quantities from laboratory to industrial scale, covering the entire lifecycle of a pharmaceutical substance. 
 

Dipharma's core technologies are: High-pressure hydrogenation, Nitration, Nitroesterification, Azide chemistry, Borane reductions, Cross-coupling reactions, Curtius reaction, Dissolving metal reduction, Enzymatic chemistry, Epichlorohydrin chemistry, Hoffman reaction, Hydrogen peroxide oxidations, Carbohydrate chemistry, Enantioselective reactions, Use of nitroalkanes (Henry reaction), Wolff-Kishner reduction. 

The Dipharma Group has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently while offering flexibility and agility to promptly solve any challenge. 
Experience you can trust 

 Dipharma 集团是一家全球性的医药合同研发生产机构（CDMO），是API，新化学分子实体（NCE）和用于仿制药以及合同生产高级中间体的领先制造商，向全球供应经DMF注册的约40个API。

凭借600多名技术精湛、高度敬业的员工，得益于美国和意大利的四家最高水平的cGMP制造工厂，以及位于意大利、美国和中国的商业销售网络，Dipharma在战略上定位于满足制药行业的动态需求。

在内部知识产权部门的配合下，我们设备齐全的研发中心，通过开发量身定制的尖端化学工艺和晶型来推动创新，以满足客户的独特需求。

自1970年以来，Dipharma在主要监管机构的不间断检查中一直保持良好的记录，它的cGMP设施 具备从实验室到商业化生产的供应能力，涵盖了药物开发的整个生命周期。

Dipharma的核心技术有:高压加氢、硝化、亚硝基酯化、叠氮化物化学、硼氢还原、交叉偶联反应、库尔提斯反应、溶解金属还原、酶化学、环氧氯丙烷化学、 霍夫曼反应、过氧化氢氧化、糖质化学、对映选择性反应、硝基烷烃使用(Henry反应)、沃尔夫基斯内尔-还原反应。

Dipharma集团有着适当的规模和各类商业化生产拓展的能力来参与全球的事务，通过有效地流程管理，灵活敏捷的机制，以快速应对市场的各种挑战。

Dipharma是你值得信赖的合作伙伴。